KLRK1 and Miyoshi myopathy: Reduction in activating receptors (NKG2D, DNAM-1, CD161) and increased expression of CD158a inhibitory Killer Immunoglobulin-like Receptor (KIR) has been described in NK cells from MM patients [213,214,215,216].